Trials / Unknown
UnknownNCT04478500
Neuroinflammation in Hypertension Study
The Role of Neuroinflammation in Hypertension.Minocycline for Resistant Hypertension: a Randomized Double Blind Placebo-Controlled Trial
- Status
- Unknown
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 60 (estimated)
- Sponsor
- Royal Perth Hospital · Academic / Other
- Sex
- All
- Age
- 45 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
To demonstrate that in patients with resistant hypertension oral treatment with minocycline via inhibition of central immune cell activation and inflammation results in reduced central sympathetic outflow and concomitant lowering of BP.
Detailed description
This is a randomized, double-blind, placebo controlled, parallel group design study aiming to compare the effects of minocycline 100mg twice daily vs matched placebo for 12 weeks on ambulatory BP and the parameters of sympathetic and immune activation
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Minocycline | Participants will be randomly assigned to receive either Minocycline 100mg twice daily or Placebo. Comprehensive testing will be performed at baseline, and at the end of the 12 week intervention phase. |
Timeline
- Start date
- 2020-07-02
- Primary completion
- 2024-08-01
- Completion
- 2025-02-01
- First posted
- 2020-07-20
- Last updated
- 2022-09-29
Locations
1 site across 1 country: Australia
Source: ClinicalTrials.gov record NCT04478500. Inclusion in this directory is not an endorsement.